Lipid 10 is a novel ionizable cationic lipid be used for delivery of therapeutic RNA to the Bone Marrow in Multiple Myeloma Using CD38-Targeted with Lipid 10-LNP.

YCT529 is a potent, selective and orally active RAR-α inhibitor.

LP0200 is the prodrug of the oral allosteric IL-17A inactivator.

The first dengue NS3-NS4B inhibitor to enter the clinic. Recently disclosed in Nature, Janssen’s JNJ-1802 is the first dengue virus NS3-NS4B protein-protein interaction inhibitor to enter the clinic.

A furan-containing insurmountable antagonist and inverse agonist of the adenosine A2A receptor for Parkinson’s disease. Kyowa Kirin’s KW-6356, or sipagladenant, is a non-xanthine A2A receptor intended to treat Parkinson’s disease.

GLPG2534 is an IRAK4 inhibitor for use as a therapeutic for inflammatory skin diseases.

TP0473292 is an adamantane carboxylic acid ester prodrug of TP0178894, a metabotropic glutamate 2 and 3 receptor antagonist for use as an antidepressant. TP0473292 has undergone phase 1 clinical trials for treatment of depression.

Overview. A common route of resistance to tuberculosis involves Mtb erm37 expression, which expresses an RNA methyltransferase that methylates the A2058 position of the 23S ribosome RNA, hindering macrolide antibiotic binding.

QR-6401 is a CDK2 inhibitor. QR-6401 demonstrated robust antitumor efficacy in an OVCAR3 ovarian cancer xenograft model via oral administration.

BDM2(Newly disclosed HIV-1 antiretroviral) is the first integrase-LEDGF/p75 allosteric HIV-1 inhibitor to clear Ph.

A protein-protein interaction inhibitor for a challenging-to-drug master transcription factor.

LY3154885 is a Human Dopamine D1 Receptor Positive Allosteric Modulator (D1 PAM EC50 = 11.7 nM) with an Improved Nonclinical Drug−Drug Interaction Risk Profile.

AZ13824374 is a highly potent and selective ATAD2 inhibitor which shows cellular target engagement and antiproliferative activity in a range of breast cancer models.

MAP855 is a novel highly potent and selective MEK1/2 kinase inhibitor with equipotent inhibition of WT and mutant MEK1/2, whose drug-like properties allow further investigation in the mutant MEK setting upon BRAF/MEK therapy.

”Compound 53” (University of Texas Southwestern Medical Center) is a stimulator of interferon (IFN) genes (STING) agonist.

TXA6101 is an FtsZ inhibitor that is associated with potent activity against clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) that are resistant to current standard-of-care antibiotics.

“compound 4e” (Chiesi Farmaceutici) is an inhaled p38α/β mitogen-activated protein kinase (MAPK) inhibitor being developed for lung inflammatory diseases.

MAGLi 432 is a novel, reversible monoacylglycerol lipase (MAGL) inhibitor.

HHS-166 shows dose-dependent inhibition of arsenite-induced stress granule (SG) formation, and liganded G3BP1 Y40 in the NTF2 dimerization domain of this essential nucleating protein for SG regulation.

AHL-030 is a potent and selective EDC3-targeted ligands. AHL-030 is also an stress granules (SGs) enhancer and results in a 2-fold increase in SGs per arsenite-treated cell.